Piper Sandler Companies (PIPR)
Bid | 325.05 |
Market Cap | 6.05B |
Revenue (ttm) | 1.58B |
Net Income (ttm) | 210.94M |
EPS (ttm) | 11.57 |
PE Ratio (ttm) | 29.55 |
Forward PE | 18.9 |
Analyst | Hold |
Dividends | $6.3 |
Ask | 352 |
Volume | 153,070 |
Avg. Volume (20D) | 142,785 |
Open | 346.75 |
Previous Close | 341.99 |
Day's Range | 340.06 - 350.93 |
52-Week Range | 202.91 - 374.77 |
Beta | 1.44 |
Ex-Dividend Date | Aug 29, 2025 |
About PIPR
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for PIPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription

1 month ago · https://thefly.com
Dollar Tree price target lowered to $108 from $112 at Piper SandlerPiper Sandler analyst Peter Keith lowered the firm's price target on Dollar Tree to $108 from $112 and keeps a Neutral rating on the shares following Q2 earnings. Q2 was solid with a 6.5% comp that wa...

1 month ago · https://thefly.com
Salesforce price target lowered to $315 from $335 at Piper SandlerPiper Sandler lowered the firm's price target on Salesforce to $315 from $335 and keeps an Overweight rating on the shares. Investor sentiment on Salesforce remained bearish going into the July-ending...

1 month ago · https://thefly.com
Ollie's Bargain Outlet price target raised to $150 from $123 at Piper SandlerPiper Sandler raised the firm's price target on Ollie's Bargain Outlet to $150 from $123 and keeps an Overweight rating on the shares. Fundamentals across the discount retailer space have improved as ...

1 month ago · https://thefly.com
Dollar Tree price target raised to $112 from $93 at Piper SandlerPiper Sandler analyst Peter Keith raised the firm's price target on Dollar Tree to $112 from $93 and keeps a Neutral rating on the shares. Fundamentals across the discount retailer space have improved...

1 month ago · https://thefly.com
Piper starts Summit Therapeutics with Neutral on high expectationsPiper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target. The firm believes investor expectations for ivonescimab are too hi...